Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome variables, such as admission to the Intensive Care Unit (ICU), to "Gerencia de Atención Integrada (GAI) de Albacete". "Complejo Hospitalario Universitario de Albacete". Albacete (Spain)", based on the files of the MXXI medical records, Information System of the Laboratory (ISL) and Pharmacy.
- EligibilityCriteria: Inclusion Criteria:  Admitted to the hospital "Complejo Hospitalario de la GAI de Albacete" Meet the SARS-CoV-2 diagnostic criteria with positive PCR They have completed at least the first dose of Calcifediol within the first 72 hours after admission, (according to protocol).  Exclusion Criteria:  Patients who do not receive the full first doseof Calcifediol within the first 72 hours. Patients for whom electronic medical record data cannot be collected. Patients with other serious intercurrent diseases (eg advanced oncological pathology). - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients admitted to the GAI Hospital Complex of Albacete, due to COVID-19 [respiratory infection confirmed by radiographic pattern of viral pneumonia and positive polymerase chain reaction (PCR)/antigen for SARS-CoV-2]. Those participants for whom there is not enough information in the files to be able to analyze the study hypotheses will be excluded from the study.  Patients meeting ALL inclusion criteria and NO exclusion criteria will be included in the study. - SamplingMethod: Non-Probability Sample